Novartis Starlix
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Company will seek a diabetes prevention claim for its type 2 diabetes drug Starlix with data generated from an 8,000 patient outcomes study, the firm tells analysts. The trial's primary endpoints will be prevention of impaired glucose tolerance progression to type 2 diabetes and improved cardiovascular outcomes. Novartis will begin enrollment by late summer, and results could be available by 2004-2005. The company is getting ready to launch the irritable bowel syndrome treatment Zelmac mid-year and the asthma therapy Xolair, which is being developed with Genentech and Tanox, by the end of the yea